Shaimaa Ismail Omar, Nagat Sobhy Mohamed, Nermeen Eldabah, Eman Abdalhakim
{"title":"评估特应性皮炎患儿血清中缺血修饰白蛋白和白细胞介素-17的水平。","authors":"Shaimaa Ismail Omar, Nagat Sobhy Mohamed, Nermeen Eldabah, Eman Abdalhakim","doi":"10.1007/s00403-024-03366-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Atopic dermatitis (AD) is the most prevalent chronic inflammatory skin disease in childhood. Interleukin 17 (IL17) is one of the pro-inflammatory cytokines that has an important role in the pathogenesis of many skin diseases including AD. Ischemia modified albumin (IMA) is an indicator of oxidative stress, inflammation and ischemia. The aim of the study was to assess the IL-17 and IMA serum levels in the children patients with AD in comparison to a control group. Additionally, the study seeks to examine the correlation between these biomarkers and their association with disease severity, disease stages, and other clinical characteristics.</p><p><strong>Methods: </strong>The case-control study enrolled two groups: (patient group: 50 children with AD) and (control group: 50 healthy age and sex-matched children). Full history was taken from all cases along with full dermatologic examination. The assessment of AD severity was conducted by using Eczema Area and Severity Index (EASI). Evaluation of IL-17 and IMA was performed by using ELISA technique.</p><p><strong>Results: </strong>There was a statistically significant elevation in the mean levels of IL-17 and IMA in patients with AD compared to the control group. A strong positive correlation was observed between IL-17 and IMA levels. Additionally, both IL-17 and IMA levels exhibited a statistically significant negative correlation with the duration of the disease and the age of the patients.</p><p><strong>Conclusion: </strong>The elevated serum levels of IL17 and IMA and their positive correlation confirm that AD is a systemic inflammatory disease influenced and associated with increased oxidative stress.</p>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Assessment of serum levels of ischemia modified albumin and interleukin-17 in children with atopic dermatitis.\",\"authors\":\"Shaimaa Ismail Omar, Nagat Sobhy Mohamed, Nermeen Eldabah, Eman Abdalhakim\",\"doi\":\"10.1007/s00403-024-03366-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Atopic dermatitis (AD) is the most prevalent chronic inflammatory skin disease in childhood. Interleukin 17 (IL17) is one of the pro-inflammatory cytokines that has an important role in the pathogenesis of many skin diseases including AD. Ischemia modified albumin (IMA) is an indicator of oxidative stress, inflammation and ischemia. The aim of the study was to assess the IL-17 and IMA serum levels in the children patients with AD in comparison to a control group. Additionally, the study seeks to examine the correlation between these biomarkers and their association with disease severity, disease stages, and other clinical characteristics.</p><p><strong>Methods: </strong>The case-control study enrolled two groups: (patient group: 50 children with AD) and (control group: 50 healthy age and sex-matched children). Full history was taken from all cases along with full dermatologic examination. The assessment of AD severity was conducted by using Eczema Area and Severity Index (EASI). Evaluation of IL-17 and IMA was performed by using ELISA technique.</p><p><strong>Results: </strong>There was a statistically significant elevation in the mean levels of IL-17 and IMA in patients with AD compared to the control group. A strong positive correlation was observed between IL-17 and IMA levels. Additionally, both IL-17 and IMA levels exhibited a statistically significant negative correlation with the duration of the disease and the age of the patients.</p><p><strong>Conclusion: </strong>The elevated serum levels of IL17 and IMA and their positive correlation confirm that AD is a systemic inflammatory disease influenced and associated with increased oxidative stress.</p>\",\"PeriodicalId\":8203,\"journal\":{\"name\":\"Archives of Dermatological Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2024-09-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of Dermatological Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00403-024-03366-6\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Dermatological Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00403-024-03366-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:特应性皮炎(AD)是儿童时期最常见的慢性炎症性皮肤病。白细胞介素 17(IL17)是促炎细胞因子之一,在包括特应性皮炎在内的多种皮肤病的发病机制中起着重要作用。缺血修饰白蛋白(IMA)是氧化应激、炎症和缺血的指标。本研究旨在评估与对照组相比,AD 儿童患者的 IL-17 和 IMA 血清水平。此外,该研究还试图探讨这些生物标志物之间的相关性及其与疾病严重程度、疾病分期和其他临床特征之间的联系:病例对照研究分为两组:(患者组:50 名 AD 儿童)和(对照组:50 名年龄和性别匹配的健康儿童)。对所有病例进行全面病史采集和全面皮肤检查。使用湿疹面积和严重程度指数(EASI)评估AD的严重程度。采用 ELISA 技术评估 IL-17 和 IMA:结果:与对照组相比,AD 患者体内 IL-17 和 IMA 的平均水平有明显的统计学升高。IL-17和IMA水平之间存在很强的正相关性。此外,IL-17 和 IMA 水平与病程和患者年龄呈统计学意义上的显著负相关:结论:血清中 IL17 和 IMA 水平的升高及其正相关性证实,AD 是一种受氧化应激增加影响并与之相关的全身性炎症性疾病。
Assessment of serum levels of ischemia modified albumin and interleukin-17 in children with atopic dermatitis.
Background: Atopic dermatitis (AD) is the most prevalent chronic inflammatory skin disease in childhood. Interleukin 17 (IL17) is one of the pro-inflammatory cytokines that has an important role in the pathogenesis of many skin diseases including AD. Ischemia modified albumin (IMA) is an indicator of oxidative stress, inflammation and ischemia. The aim of the study was to assess the IL-17 and IMA serum levels in the children patients with AD in comparison to a control group. Additionally, the study seeks to examine the correlation between these biomarkers and their association with disease severity, disease stages, and other clinical characteristics.
Methods: The case-control study enrolled two groups: (patient group: 50 children with AD) and (control group: 50 healthy age and sex-matched children). Full history was taken from all cases along with full dermatologic examination. The assessment of AD severity was conducted by using Eczema Area and Severity Index (EASI). Evaluation of IL-17 and IMA was performed by using ELISA technique.
Results: There was a statistically significant elevation in the mean levels of IL-17 and IMA in patients with AD compared to the control group. A strong positive correlation was observed between IL-17 and IMA levels. Additionally, both IL-17 and IMA levels exhibited a statistically significant negative correlation with the duration of the disease and the age of the patients.
Conclusion: The elevated serum levels of IL17 and IMA and their positive correlation confirm that AD is a systemic inflammatory disease influenced and associated with increased oxidative stress.
期刊介绍:
Archives of Dermatological Research is a highly rated international journal that publishes original contributions in the field of experimental dermatology, including papers on biochemistry, morphology and immunology of the skin. The journal is among the few not related to dermatological associations or belonging to respective societies which guarantees complete independence. This English-language journal also offers a platform for review articles in areas of interest for dermatologists and for publication of innovative clinical trials.